Fathom Pharmaceuticals (PHAT) Q1 2026: New-to-Brand Share Hits 45% Among Top GI Prescribers, Reinforcing First-Mover Advantage
Fathom Pharmaceuticals’ Q1 2026 results reveal decisive traction in gastroenterology with Vaquesna’s new-to-brand prescription share climbing sharply among top prescribers, validating the GI-focused strategy and setting up a path to operating profitability. Management’s disciplined expense posture and commercial execution are building durable market presence ahead of expected competitive entry, while near-term cash flow and guidance remain intact. Investors should watch for further GI share gains, persistence metrics, and the impact of a second PCAB entrant in 2027.
Summary
- GI Channel Penetration Deepens: Vaquesna’s new-to-brand prescription share among leading gastroenterologists signals accelerating adoption.
- Expense Discipline Maintained: Expansion of the sales force and R&D investment balanced by year-on-year cost reductions.
- Competitive Positioning Strengthens: First-mover momentum in the PCAB class solidifies Fathom’s base ahead of potential new entrants.
Performance Analysis
Fathom delivered a quarter marked by triple-digit revenue growth year-over-year, reflecting the impact of its GI-focused commercial pivot and the scaling of its Vaquesna, PCAB (potassium-competitive acid blocker) franchise. While sequential revenue growth was modest, management attributed this to expected seasonality, market access dynamics, and the timing of new sales hires entering the field. Prescription volumes and covered scripts both saw robust expansion, with new prescription highs recorded in early Q2, suggesting a strong exit rate from the quarter.
Cash operating expenses rose sequentially, driven by the full deployment of nearly 50 new sales reps, the annual sales meeting, and accelerated enrollment in the EOE (eosinophilic esophagitis) Phase II trial. However, year-over-year operating expenses declined 43%, highlighting ongoing cost discipline. Gross margin remained strong at approximately 80%, and net cash usage was in line with expectations, supporting management’s confidence in achieving operating profitability by Q3 2026 and positive cash flow in 2027.
- Prescription Growth Outpaces Coverage: Total scripts filled grew 115% YoY, while covered scripts increased 91%, reflecting the impact of cash pay options for Medicare patients.
- Sales Force Expansion Complete: Over 290 reps now focused on high-frequency GI calls, underpinning future growth.
- Persistence and Refills Drive Durability: Patients starting on Vaquesna in 2024 averaged six bottles dispensed over 12 months, with additional restarts observed.
Management maintained all key financial guidance ranges, expecting revenue to be weighted toward the second half of the year with a stable gross-to-net discount and controlled expense cadence.
Executive Commentary
"We believe we're on track to potentially achieving 1 billion in annual revenue from gastroenterology prescriptions with the potential for a second billion from primary care prescriptions as patients cycle back to share their Vaquesna experience with their PCP and we evolve our sales and marketing focus to include this segment in the future."
Steve Basta, President and CEO
"Importantly, we continue to demonstrate expense discipline across the organization with the year-on-year cash operating expenses down about 43% compared to Q1 2025... Based on our current operating plan, we believe our cash on hand along with the anticipated future cash generated from operations will be sufficient to invest in our business, satisfy all outstanding debt obligations at all time without the need for another debt or equity raise."
Sanjeev Narula, Chief Financial and Business Officer
Strategic Positioning
1. Gastroenterology-First Commercial Focus
Fathom’s pivot to a GI-centric sales model has been validated by new-to-brand prescription (NBRX) data: among the top 300 GI prescribers, Vaquesna achieved 45% NBRX share, and over 30% among the top 3,000. This metric—tracking patients switched to Vaquesna for the first time—serves as a leading indicator for future total prescription (TRX) growth and is a core internal measure of commercial effectiveness.
2. Sales Force Scale and Execution
With the full deployment of 290+ sales reps, Fathom has completed its alignment for high-frequency GI engagement. The company is now positioned to deepen penetration among gastroenterologists, with enhanced HCP (healthcare provider) marketing and educational programs supporting field execution. Management expects continued improvement in both NBRX and TRX metrics as the sales force gains tenure and coverage expands.
3. Durable First-Mover Advantage in PCABs
Vaquesna remains the only branded PCAB in the US market, and management sees category awareness set to rise with the anticipated entry of a second PCAB competitor in 2027. Fathom’s strategy is to entrench prescribing habits and patient loyalty now, leveraging superior clinical data (93% healing rate in erosive esophagitis) and early physician feedback. Management expects that increased class awareness will expand the overall PCAB market, benefiting the incumbent leader.
4. R&D and Indication Expansion
Enrollment in the EOE Phase II trial is ahead of schedule, suggesting strong clinical interest and possible future label expansion. Management is also exploring as-needed dosing and new patient populations, including those with GLP-1-induced GERD, positioning Vaquesna for broader utility and IP opportunities.
5. Future Primary Care Opportunity
While primary care is not yet a commercial focus, early signs of PCP (primary care physician) uptake via patient-driven demand are emerging. Management sees this as a natural next phase, with patient advocacy and real-world outcomes expected to drive PCP adoption over the coming years.
Key Considerations
Q1 2026 was a pivotal quarter for Fathom, demonstrating both operational momentum and strategic clarity as it seeks to entrench Vaquesna’s position in the GI market before competitive dynamics shift.
Key Considerations:
- New-to-Brand Share as Growth Engine: 45% NBRX share among top GI writers signals robust new patient conversion and future refill potential.
- Sales Force Productivity Ramp: The recent expansion is expected to yield further prescription growth as reps mature in their territories.
- Seasonality and Coverage Dynamics: Q1 reflected higher cash pay scripts due to insurance resets; normalization is expected in subsequent quarters.
- Expense Management Supports Profitability Path: Despite commercial and R&D investment, cost discipline positions Fathom for operating profitability in Q3.
- Pipeline and Indication Expansion: Accelerated EOE trial enrollment and exploration of new patient cohorts could unlock incremental growth levers.
Risks
Competitive entry from a second PCAB in 2027 could intensify pricing and market access pressure, although Fathom’s first-mover advantage and entrenched physician relationships may mitigate immediate share loss. Market access hurdles, payer dynamics, and evolving prescription coverage ratios remain watchpoints, as do execution risks around sales force productivity and the pace of refill persistence. Regulatory or reimbursement changes could also impact the durability of current growth rates.
Forward Outlook
For Q2 2026, Fathom expects:
- Continued sequential revenue growth, with prescription volumes building on late Q1 momentum.
- A modest step-up in operating expenses, reflecting a full quarter of expanded sales force and accelerated EOE trial spend.
For full-year 2026, management maintained guidance:
- Net revenue between $320 million and $345 million.
- Gross-to-net discount in the 55% to 59% range and gross margin around 80%.
- Cash operating expenses (ex-SBC) of $235 million to $255 million.
- Operating profitability (ex-SBC) by Q3 2026; positive cash flow in 2027.
Management highlighted:
- Revenue will be second-half weighted, mirroring 2025 patterns.
- Expense levels to stabilize after Q2 as sales force and R&D investments normalize.
Takeaways
Fathom’s Q1 2026 results reinforce the company’s GI-focused strategy and demonstrate early signs of durable market leadership in the PCAB class.
- Commercial Execution Drives Market Share: The company’s focus on GI specialists is yielding measurable gains in new patient starts and future refill durability, supported by best-in-class clinical outcomes.
- Expense Control Underpins Profitability Path: Operating discipline and capital structure enhancements provide financial flexibility as growth investments ramp.
- Watch for Competitive and Market Access Shifts: The anticipated arrival of a second PCAB entrant and evolving payer dynamics could reshape the competitive landscape in 2027 and beyond.
Conclusion
Fathom Pharmaceuticals’ Q1 2026 performance validates its focused GI strategy, with new-to-brand prescription share and field execution driving a credible path to operating profitability. The company’s strong clinical data, commercial discipline, and measured approach to future expansion provide a solid foundation as the PCAB category evolves.
Industry Read-Through
Fathom’s experience underscores the importance of new-to-brand share and prescriber depth for specialty pharma launches, especially in new therapeutic classes like PCABs. The company’s ability to convert early clinical data into durable commercial adoption is a blueprint for other first-mover franchises. As the GI and acid suppression market prepares for a second PCAB entrant, category awareness and physician education will likely accelerate, benefiting established players with entrenched sales infrastructure. The evolving payer landscape and patient-driven demand patterns are relevant for all specialty therapeutics seeking to expand from specialist to primary care channels.